Segment Reporting

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Segment Reporting

Note 12 – Segment Reporting

In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy. The financial results of the Company’s operations are managed and reported to the Chief Executive Officer who is considered the Company’s chief operating decision maker (CODM), on a consolidated basis.

The CODM assesses performance and allocates resources based on the Company’s consolidated statements of operations and key components and processes of the Company’s operations are managed centrally. Segment asset information is not used by the CODM to allocate resources.

As a single reportable segment entity, the Company’s segment performance measure is net income / (loss) attributable to shareholders. Significant segment expenses, as provided to the CODM, are presented below:

	Quarter Ended March 31,
	2025			2024
Segment expenses
Salaries and Benefits	$	3,829,221		$	4,183,270
Professional fees		1,127,046			1,077,266
General administrative expenses		344,354			364,662
Clinical development expenses		2,432,198			3,113,509
Other development expenses		1,372,939			1,358,921
Total operating and segment expenses	$	9,105,758		$	10,097,627
Interest income		377,849			668,895
Interest expense		(930,878	)		(1,174,745	)
Benefit from income taxes		1,169,820			–
Segment and consolidated net loss	$	(8,488,967	)	$	(10,603,477	)